Sign in
TerminatedNo phase

The isCGM Use and Hypoglycemic Episodes and Fear of Hypoglycemia in Newly Diagnosed Type 1 Diabetes

Key facts

Who runs it
Jagiellonian University
Where
Poland4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
28 people enrolled
Started
1 May 2022
Ended
31 May 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Intermittently Scanned Continuous Glucose Monitoring
  • Standard Blood Glucose Monitoring
Record updated
2 October 2024
Why it stopped
The study ended early due to CGM reimbursement policy changes, after that most patients eligible for the study could have isCGM reimbursed.

Who can take part

Age
18 years to 35 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Newly diagnosed type 1 diabetes (diagnosed based on the WHO criteria) no later than 6 months after the diagnosis
  • Insulin therapy: multiple daily injections,
  • In the investigator's opinion, the participant must be technically capable of using the FreeStyle Libre system

Who cannot take part

  • Pump therapy
  • Oral steroid therapy
  • Hospitalization for any reason other than the newly diagnosed type 1 diabetes 6 months prior to inclusion
  • Known allergy to medical adhesives
  • Unstable coronary heart disease
  • Cancer
  • Psychiatric disorders
  • Severe end-organ damage (kidney, liver, etc) or any uncontrolled disorder
  • Current or past use of any continuous glucose monitoring system
  • Participating in another clinical trial that could affect glucose measurements or glucose management
  • Pregnancy or planning pregnancy within the study duration
  • Breast feeding
  • Dialysis treatment
  • Having a pacemaker
  • Cystic fibrosis
  • In the investigator's opinion, if the participant is considered unsuitable for inclusion in the study for any other reason

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this trial is to investigate the impact of FreeStyle Libre use compared to SMBG on hypoglycemia episodes and fear of hypoglycemia in adults aged 18-35 with newly diagnosed type 1 diabetes.

Read full original descriptionShow less

This trial is conducted in university centers in Poland (Bialystok, Krakow, Poznan, Zabrze).

The 2 groups in the trial

  • FreeStyle LibreTreatment being tested

    FreeStyle Libre for 4 weeks. All subjects will wear a masked sensor (FreeStyle Libre Pro) for 14 days prior to randomisation.

    Treatment: Intermittently Scanned Continuous Glucose Monitoring

  • SMBGExisting treatment, for comparison

    Subjects randomised to the control group will monitor their blood glucose with standard blood glucose meters. A 14-day FreeStyle Libre Pro is included for these subjects from day 14 to day 28 to collect glycaemic data for comparison to the intervention group of the study. All subjects will wear a masked sensor (FreeStyle Libre Pro) for 14 days prior to randomisation.

    Treatment: Standard Blood Glucose Monitoring

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Impact of the isCGM Use on the Hypoglycemic Episodes and Fear of Hypoglycemia in Patients With Newly Diagnosed Type 1 Diabetes
Publications
Record updated
2 October 2024